samedan logo
 
 
spacer
home > ict > autumn 2008 > more than a lifestyle drug
PUBLICATIONS
International Clinical Trials

More than a Lifestyle Drug

Urological diseases or dysfunctions will afflict most of us at some point in our adult lives and will have a severe negative impact on quality of life. Urological conditions range from common ‘bothersome’ complaints such as urinary incontinence, benign prostatic hyperplasia (BPH) and male sexual dysfunction, profoundly uncomfortable and painful conditions such as kidney stones and interstitial cystitis, and life-threatening prostate, bladder and kidney cancers.

The underlying aetiology of certain urological diseases is well understood and has resulted in the introduction of several ‘blockbuster’ drugs during the last decade designed for the treatment of overactive bladder (OAB), BPH and erectile dysfunction. Few effective pharmaceutical remedies are available for more complex urological conditions such as stress urinary incontinence, premature ejaculation, chronic prostatitis and interstitial cystitis.

Current urological drug development is attempting to address these significant unmet or poorly met medical needs, and to bring more effective and better tolerated...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Mike Wyllie has over 25 years of experience in senior management level positions within the pharmaceutical industry. He started out as Director of Biology at Pfizer from 1984-1998. Subsequently, he established Urodoc Ltd, a strategic planning and medical education company servicing the pharmaceutical industry. In 2003, he co-founded Plethora Solutions Ltd, a company specialising in IP generation, urological and andrological drug development and Phase II clinical trials. He is also a non-executive Director and CSO of the medical technology company Zi Medical Plc. In 2006 Mike became founding partner of Global Pharma Consulting Ltd, which provides interim management support across a wide range of functions to medium and small biopharmaceutical and medical technology companies. In December 2006 he helped to float the Chinese pharmaceutical company Taihua (AIM:TAIH) and joined the boards of Bactomed Ltd and Bluescope Ltd. Mike is named inventor on over 100 methods of treatment, formulation and device patents.
spacer
Mike Wyllie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AirBridgeCargo Airlines steps into COVID-19 vaccine transportation phase

AirBridgeCargo Airlines, part of Volga-Dnepr Group, has accomplished its first COVID-19 vaccine transportation from Beijing (China). The delivery of CanSino's Covid-19 vaccine has been orchestrated in partnership with UPS/Marken onboard one of the carrier’s Boeing 747 freighter.
More info >>

White Papers

Environmental Factors in Data Centres

Dycem

In addition to temperature and humidity, there are many more constraints in the environment that increase failure rates, explains Emilio Sapiña of Secure Techincal Rooms.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement